The United States might see one of the steepest increases in the country’s uninsured rate in years.

CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.

NIAID is preparing for the possibility of future variants evading protection against currently available COVID-19 vaccines.

While vaccination typically provides robust protection against severe disease, they’re less effective for immunocompromised people.

Novel therapies, improved technologies and a better understanding of the immune system could yield broad dividends.

Immunocompromised people ages 12 and older are also eligible for an additional shot.

Protecting the immunocompromised is not only a matter of health equity, it’s critical to ending the pandemic.

Researchers showed that B cells evolve after COVID-19 vaccination to help improve protection against SARS-CoV-2 over time.

The CDC’s move triggered mixed feelings from the public and laid bare a split within the health care community.

Transplant recipients, people with advanced HIV and certain people with cancer or autoimmune diseases can get an additional vaccine dose.